Showing 4261-4270 of 5636 results for "".
- Kiora Reports KIO-101 is Safe and Tolerable for Dry Eye Diseasehttps://modernod.com/news/kiora-reports-kio-101-is-safe-and-tolerable-for-dry-eye-disease/2480512/Kiora Pharmaceuticals announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a driver of dry eye disease. The results demonstrated favorable safe
- I-MED Pharma USA Gains Exclusive Distribution Rights for ESW Vision’s E>Eye and Tearcheck in the United Stateshttps://modernod.com/news/i-med-pharma-usa-gains-exclusive-distribution-rights-for-esw-visions-eeye-and-tearcheck-in-the-united-states/2480505/I-MED Pharma has announced the expansion of their strategic partnership with ESW Vision in France to be their exclusive distributor in the United States. Through I-MED Pharma USA, two dry eye devices will be available directly to all eye care professionals across the country. E>Eye i
- Aerie Signs License Agreement With Santen for Rhopressa and Rocklatan in Europe and Several Other Regionshttps://modernod.com/news/aerie-concludes-exclusive-license-agreement-with-santen-for-rhopressa-and-rocklatan-in-europe-and-several-other-regions/2480495/Aerie Pharmaceuticals announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa/Rhokiinsa (netarsudil ophthalmic solution) 0.02% and Rocklatan/Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expan
- GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of Lumevoq Vector DNA in Contralateral Eyes After Unilateral Injectionhttps://modernod.com/news/gensight-biologics-announces-publication-of-non-human-primate-study-reporting-presence-of-lumevoq-vector-dna-in-contralateral-eyes-after-unilateral-injection/2480491/GenSight Biologics announced that the journal "Molecular Therapy – Methods and Clinical Development" has published the results of a mechanistic study demonstrating the transfer of Lumevoq vector DNA from the injected eyes to the non-injected eyes of non-human prim
- Notal Vision Monitoring Center Reports AI Analysis of 10 Million ForeseeHome AMD Home Monitoring Testshttps://modernod.com/news/notal-vision-monitoring-center-reports-ai-analysis-of-10-million-foreseehome-amd-home-monitoring-tests/2480482/The Notal Vision Monitoring Center celebrates the artificial intelligence (AI) based analysis of the ten millionth test performed by over 20,000 patients with the FDA-cleared ForeseeHome devic
- Inspecs Acquires Hardy Amies Brandhttps://modernod.com/news/inspecs-acquires-hardy-amies-brand/2480476/Inspecs, a designer, manufacturer and distributor of eyewear frames and lenses, has announced the acquisition of the Hardy Amies brand, including all global intellectual property rights. Terms of the deal were not disclosed. Hardy Amies was founded by Sir Hardy Amie
- Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europehttps://modernod.com/news/nicox-is-granted-patent-for-blepharitis-product-candidate-ncx-4251-in-europe/2480459/Nicox SA announced that patent EP 3,769,753, expiring in 2040 and covering the company’s product candidate in development for blepharitis, NCX 4251, has been issued by the European Patent Office (EPO). The patent covers ophthalmic suspensions comprising a specific form of fluticas
- Edenlux Launches Campaign for Otus Personal EYE-Trainerhttps://modernod.com/news/edenlux-launches-campaign-for-otus-personal-eye-trainer/2480458/The Otus personal eye-trainer, which was created by Edenlux, has launched a campaign through Indiegogo. The device uses training called Vision Therapy to relieve the stress of the eyes. Vision Therapy is an exercise that repeats the contraction and relaxation of the
- jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapyhttps://modernod.com/news/jcyte-identifies-key-anatomical-biomarker-predictive-of-substantial-restoration-of-visual-function-in-retinitis-pigmentosa-patients-treated-with-jcell-therapy/2480452/jCyte announced key findings presented at AAO 2021 which demonstrated that retinitis pigmentosa (RP) patients with a baseline central visual field diameter greater than 20 degrees had a profound response to jCell treatment in its phase 2b study, the largest randomized clinical trial ever con
- Spherix Global Insights Introduces Ophthalmology to Suite of Independent Market Research and Intelligence Serviceshttps://modernod.com/news/spherix-global-insights-introduces-ophthalmology-to-suite-of-independent-market-research-and-intelligence-services/2480450/Spherix Global Insights, a market research firm providing independent coverage of select specialty markets, officially cut the ribbon on their ophthalmology franchise. Spherix derives actionable insights from its frequent, commercially-focused, primary market research, which i